Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith L Knutson

Showing results (141-150 of 147) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 147 results.
Nature Communications|April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancerJodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Plos One|February 6, 2013
Inherited variants in regulatory T cell genes and outcome of ovarian cancerEllen L Goode, Melissa DeRycke, Kimberly R Kalli, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 18, 2014
Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancerMatthew S Block, Bridget Charbonneau, Robert A Vierkant, et al.
Cancer Immunology Research|April 26, 2014
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcomeBridget Charbonneau, Kirsten B Moysich, Kimberly R Kalli, et al.
Cancer Research|November 26, 2013
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10Bridget Charbonneau, Matthew S Block, William R Bamlet, et al.
Oncotarget|August 18, 2016
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancerShalaka S Hampras, Lara E Sucheston-Campbell, Rikki Cannioto, et al.
Pageof 15

Showing results (141-150 of 147) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
Nature Communications|April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancerJodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Plos One|February 6, 2013
Inherited variants in regulatory T cell genes and outcome of ovarian cancerEllen L Goode, Melissa DeRycke, Kimberly R Kalli, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 18, 2014
Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancerMatthew S Block, Bridget Charbonneau, Robert A Vierkant, et al.
Cancer Immunology Research|April 26, 2014
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcomeBridget Charbonneau, Kirsten B Moysich, Kimberly R Kalli, et al.
Cancer Research|November 26, 2013
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10Bridget Charbonneau, Matthew S Block, William R Bamlet, et al.
Oncotarget|August 18, 2016
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancerShalaka S Hampras, Lara E Sucheston-Campbell, Rikki Cannioto, et al.
Pageof 15